T J Matthews

Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides.

A J Langlois, B. Haynes, D. Bolognesi, 1988, Proceedings of the National Academy of Sciences of the United States of America.

Polyvalent human immunodeficiency virus synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopes.

J. Berzofsky, B. Haynes, R. Scearce, 1989, Journal of immunology.

Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2.

M Salgo, T. Kirkland, T. Matthews, 2006, AIDS research and human retroviruses.

HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope.

A J Langlois, J. Ghrayeb, M. Robert-Guroff, 1986, Science.

Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.

T. Matthews, C. McDanal, C. Wild, 1994, Proceedings of the National Academy of Sciences of the United States of America.

Human T-cell lymphotropic virus IIIB glycoprotein (gp120) bound to CD4 determinants on normal lymphocytes and expressed by infected cells serves as target for immune attack.

A J Langlois, H. Lyerly, D. Bolognesi, 1987, Proceedings of the National Academy of Sciences of the United States of America.